Claris Lifesciences Ltd (CLAI.BO) Key Developments | Reuters.com
Edition:
United States

Claris Lifesciences Ltd (CLAI.BO)

CLAI.BO on Bombay Stock Exchange

218.50INR
5:59am EDT
Change (% chg)

Rs1.95 (+0.90%)
Prev Close
Rs216.55
Open
Rs217.50
Day's High
Rs223.65
Day's Low
Rs216.95
Volume
36,404
Avg. Vol
94,954
52-wk High
Rs266.00
52-wk Low
Rs126.10

Latest Key Developments (Source: Significant Developments)

Claris Lifesciences announces receipt of EIR from US FDA
Monday, 30 May 2016 02:48am EDT 

Claris Lifesciences Ltd : Claris lifesciences ltd.- Claris announces receipt of EIR from the US FDA . Claris lifesciences ltd.- US FDA concluded that facility near ahmedabad was found to be acceptable . Co expects 5-7 ANDA approvals in near future .  Full Article

Claris Lifesciences March-qtr net profit down about 66 pct
Friday, 6 May 2016 08:30am EDT 

Claris Lifesciences Ltd : Recommends final dividend of INR 2 per share . Says March-quarter consol net profit 35.7 million rupees versus net profit of 104.4 million rupees year ago . Says March-quarter consol net sales 1.67 billion rupees versus 1.55 billion rupees year ago .  Full Article

Claris Lifesciences Ltd announces appointment of statutory auditors
Wednesday, 23 Sep 2015 04:41am EDT 

Claris Lifesciences Ltd:Announces appointment of Shah & Shah Associates, Chartered Accountants, Ahmedabad as the statutory auditors.  Full Article

Claris Lifesciences Ltd confirms patent challenge for generic version of PROPOFOL in USA
Tuesday, 23 Dec 2014 08:30am EST 

Claris Lifesciences Ltd:Files a New Drug Application (ANDA) for propofol for Injection, 10mg/ml with the US FDA.Company's ANDA is a generic version of DIPRIVAN, which is indicated fir general anaesthesia for surgery or other medical procedures.Fresenius Kabi USA, INc has files a suit against company on Dec. 19 in US court, seeking to prevent company from Commercializing its ANDA prior to expiration of its existing patent on Dec. 01, 2024.  Full Article